ArQule (ARQL) Receiving Favorable Media Coverage, Accern Reports

Headlines about ArQule (NASDAQ:ARQL) have trended positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ArQule earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.6254166258702 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

ArQule (ARQL) traded up $0.01 during mid-day trading on Friday, hitting $1.83. 198,307 shares of the company were exchanged, compared to its average volume of 293,202. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45. ArQule has a 12-month low of $0.92 and a 12-month high of $1.98. The stock has a market capitalization of $159.41, a price-to-earnings ratio of -4.58 and a beta of 1.38.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. During the same period last year, the company earned ($0.08) earnings per share. sell-side analysts forecast that ArQule will post -0.39 earnings per share for the current fiscal year.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine upgraded shares of ArQule from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th.

ILLEGAL ACTIVITY NOTICE: “ArQule (ARQL) Receiving Favorable Media Coverage, Accern Reports” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2018/01/13/arqule-arql-receiving-favorable-media-coverage-accern-reports.html.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Insider Buying and Selling by Quarter for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply